Express News | Editas Medicine Inc : RBC Cuts Target Price to $8 From $11
Editas Medicine (NASDAQ:EDIT) Investors Are Sitting on a Loss of 90% If They Invested Three Years Ago
Synthetic Immunology Market Report 2024 With Profiles of ADC Therapeutics, BioNTech, Camena Bioscience, CRISPR Therapeutics, Editas Medicine, Sherlock Biosciences, Synlogic Therapeutics & Synthego
Is Editas Medicine, Inc. (EDIT) One of the Best Biotech Penny Stocks to Buy Now?
What Makes Editas Medicine, Inc. (EDIT) One of the Best Small-Cap Stocks With Highest Upside Potential?
SeqWell Launches Loaded-transposase Portfolio to Support Expanding Use of NGS-based Gene Editing Analysis Methods
Tagify off-the-shelf and custom loaded-transposase reagents provide reliability and scalability to tagmentation-based on- & off-target gene editing analysisBEVERLY, Mass.--(BUSINESS WIRE)--#NGS--seqWe
Shareholders in Editas Medicine (NASDAQ:EDIT) Have Lost 87%, as Stock Drops 17% This Past Week
It's not possible to invest over long periods without making some bad investments. But really bad investments should be rare. So consider, for a moment, the misfortune of Editas Medicine, Inc. (NASD
Unveiling 5 Analyst Insights On Editas Medicine
Throughout the last three months, 5 analysts have evaluated Editas Medicine (NASDAQ:EDIT), offering a diverse set of opinions from bullish to bearish.The following table summarizes their recent rating
Editas Medicine Is Maintained at Perform by Oppenheimer
Editas Medicine Is Maintained at Perform by Oppenheimer
Oppenheimer Maintains Editas Medicine(EDIT.US) With Hold Rating, Maintains Target Price $12
Oppenheimer analyst Jay Olson maintains $Editas Medicine(EDIT.US)$ with a hold rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of 44.2% and a t
BofA Securities Maintains Editas Medicine(EDIT.US) With Hold Rating, Cuts Target Price to $13
BofA Securities analyst Greg Harrison maintains $Editas Medicine(EDIT.US)$ with a hold rating, and adjusts the target price from $15 to $13.According to TipRanks data, the analyst has a success rate o
Editas Medicine Says Its Gene Editing Potential Treatment for Sickle-Cell Disease Found Well-Tolerated in Phase 1/2 Trial
Editas Medicine (EDIT) said Friday that new data in a phase 1/2 trial of its gene-editing cell therapy medicine renizgamglogene autogedtemcel showed its was "well-tolerated" and had a safety profile c
Editas Medicine Reveals Updated Safety And Efficacy Results From The RUBY Trial Of Reni-Cel In 18 Sickle Cell Patients At EHA
All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusionPatients had early normalization of total hemoglobin with a mean within t
Express News | Editas Medicine Inc - All Patients Treated in Edithal Trial Maintained Hemoglobin Levels Above Transfusion Threshold and Are Transfusion-Free
Express News | Editas Medicine Announces New Safety and Efficacy Data From the Edithal Trial of Reni-Cel in 7 Patients With Transfusion-Dependent Beta Thalassemia, Presented at the European Hematology Association (Eha) Annual Congress
Form 144 | Editas Medicine(EDIT.US) Officer Proposes to Sell 127.68K in Common Stocks
SEC FILLINGS DISCLOSED/ May 31, $Editas Medicine(EDIT.US)$ Officer O'Neill Gilmore Neil intends to sell 24,000 shares of its common stock on Jun 3, with a total market value of approximately $127.68K.
The Analyst Verdict: Editas Medicine In The Eyes Of 4 Experts
Across the recent three months, 4 analysts have shared their insights on Editas Medicine (NASDAQ:EDIT), expressing a variety of opinions spanning from bullish to bearish.The table below offers a conde
Editas Medicine Is Maintained at In-Line by Evercore ISI Group
Editas Medicine Is Maintained at In-Line by Evercore ISI Group
Express News | Editas Medicine Inc : Evercore ISI Cuts Target Price to $7 From $15
Azzur Cleanrooms on Demand Grand Opening in Devens, MA Brings Together Local, State and Life Sciences Leaders
DEVENS, Mass., May 28, 2024 /PRNewswire/ -- Azzur Cleanrooms on Demand, a market-leading service provider for life sciences GxP manufacturing and testing capacity, recently hosted a Grand Opening and